Ruth Ruddle

1.8k citations

23 papers · 652 · h-index 12

Impact in

Cancer Research
- Cancer, Hypoxia, and Metabolism
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer
- Wnt/β-catenin signaling in development and cancer
- Cancer-related gene regulation

Papers in

Molecular Biology 15
- PI3K/AKT/mTOR signaling in cancer 6
- Biochemical and Molecular Research 4
Cancer Research 8
- Cancer, Hypoxia, and Metabolism 6

Co-authors: Florence I. Raynaud (20 shared papers)Paul Workman (8 shared papers)Suzanne A. Eccles (6 shared papers)Melanie Valenti (4 shared papers)Michelle D. Garrett (7 shared papers)Alexis de Haven Brandon (3 shared papers)Ian Collins (4 shared papers)John Caldwell (3 shared papers)
Journals: Journal of Clinical Oncology (4 papers)Molecular Cancer Therapeutics (3 papers)Cancer Research (3 papers)Clinical Cancer Research (2 papers)British Journal of Cancer (2 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Ruth Ruddle

21 papers receiving 646 citations

Peers

Countries citing papers authored by Ruth Ruddle

Since Specialization

Citations

This map shows the geographic impact of Ruth Ruddle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Ruddle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Ruddle more than expected).

Fields of papers citing papers by Ruth Ruddle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Ruddle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Ruddle. The network helps show where Ruth Ruddle may publish in the future.

Co-authors

The 25 scholars most cited alongside Ruth Ruddle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ruth Ruddle Line = papers co-authored together Ruth Ruddle links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo Clinical Cancer Research ·Jane Renshaw, Kathryn R. Taylor, Ryan T. Bishop, Melanie Valenti, Alexis de Haven Brandon, Sharon Gowan, Suzanne A. Eccles, Ruth Ruddle, Louise D. Johnson, Florence I. Raynaud, Joanna Selfe, Khin Thway, Torsten Pietsch, Andrew D.J. Pearson, Janet Shipley	2013	110
2	A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription Cancer Research ·Kenneth Ewan, Bożena Pająk, Mark Stubbs, Helen Todd, Olivier Barbeau, Camilo Quevedo, Hannah Botfield, Rodrigo Young, Ruth Ruddle, Lee Samuel, Alysia Battersby, Florence I. Raynaud, Nicholas D. Allen, Stephen W. Wilson, Branko Latinkic, Paul Workman, Edward McDonald, Julian Blagg, Wynne Aherne, Trevor Dale	2010	86
3	Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration Journal of Medicinal Chemistry ·John Caldwell, Thomas G. Davies, Alastair Donald, Tatiana McHardy, Martin Rowlands, G. Wynne Aherne, L.K. Hunter, Kevin Taylor, Ruth Ruddle, Florence I. Raynaud, Marcel L. Verdonk, Paul Workman, Michelle D. Garrett, Ian Collins	2008	74
4	Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt) Journal of Medicinal Chemistry ·Tatiana McHardy, John Caldwell, Kwai-Ming J. Cheung, Lisa J. Hunter, Kevin Taylor, Martin Rowlands, Ruth Ruddle, Alan T. Henley, Alexis de Haven Brandon, Melanie Valenti, Thomas G. Davies, Lynsey Fazal, Lisa C. A. Seavers, Florence I. Raynaud, Suzanne A. Eccles, G. Wynne Aherne, Michelle D. Garrett, Ian Collins	2010	67
5	Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 Molecular Cancer Therapeutics ·Timothy A. Yap, Mike I. Walton, Lisa-Jane K. Hunter, Melanie Valenti, Alexis de Haven Brandon, Paul D. Eve, Ruth Ruddle, Simon P. Heaton, Alan T. Henley, Lisa Pickard, Gowri Vijayaraghavan, John Caldwell, Neil T. Thompson, Wynne Aherne, Florence I. Raynaud, Suzanne A. Eccles, Paul Workman, Ian Collins, Michelle D. Garrett	2010	59
6	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors Clinical Cancer Research ·Robert McLeod, Rajiv Kumar, Dionysis Papadatos-Pastos, Joaquı́n Mateo, Jessica Brown, Alvaro Ingles Garces, Ruth Ruddle, Shaun Decordova, Simone Jueliger, Roberta Ferraldeschi, Óscar Maiques, Victoria Sanz‐Moreno, Paul S. Jones, Stephanie Traub, Gavin Halbert, Sarah Mellor, Karen E. Swales, Florence I. Raynaud, Michelle D. Garrett, Udai Banerji	2020	52
7	A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. PubMed ·Beatrice Seddon, Geoffrey S. Payne, Laura K. Simmons, Ruth Ruddle, Rachel Grimshaw, Siew Kiang Tan, Alison Turner, Florence I. Raynaud, Gavin Halbert, Martin O. Leach, Ian Judson, Paul Workman	2003	37
8	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance Cancer Research ·Orli Yogev, Karen Barker, Arti Sikka, Gilberto S. Almeida, Albert Hallsworth, Laura Smith, Yann Jamin, Ruth Ruddle, Alexander Koers, Hannah Webber, Florence I. Raynaud, Sergey Popov, Chris Jones, Kevin Petrie, Simon P. Robinson, Hector C. Keun, Louis Chesler	2016	32
9	An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models Cancer Chemotherapy and Pharmacology ·Udai Banerji, Nivedita Sain, Swee Y. Sharp, Melanie Valenti, Yasmin J. Asad, Ruth Ruddle, Florence I. Raynaud, Michael I. Walton, Suzanne A. Eccles, Ian Judson, Ann L. Jackman, Paul Workman	2008	30
10	The Phosphoinositide-Specific Phospholipase C Inhibitor U73122 (1-(6-((17β-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) Spontaneously Forms Conjugates with Common Components of Cell Culture Medium Drug Metabolism and Disposition ·Nicola E. Wilsher, Will Court, Ruth Ruddle, Yvette Newbatt, Wynne Aherne, Peter Sheldrake, Neil P. Jones, Matilda Katan, Suzanne A. Eccles, Florence I. Raynaud	2007	28
11	A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy British Journal of Cancer ·C P Lee, Geoffrey S. Payne, Alain Oregioni, Ruth Ruddle, S. Tan, Florence I. Raynaud, David Eaton, Michael J. Campbell, Kenneth R. Cross, Gavin Halbert, Michaël Tracy, J.P. McNamara, Beatrice Seddon, Martin O. Leach, Paul Workman, Ian Judson	2009	27
12	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors. Journal of Clinical Oncology ·Udai Banerji, Alvaro Ingles Garces, Vasiliki Michalarea, Ruth Ruddle, Florence I. Raynaud, Ruth Riisnaes, Daniel Nava Rodrigues, Nina Tunariu, Joanna C. Porter, Sarah Ward, Mona Parmar, Alison Turner, Satyanarayana Seeramreddi, Emma Hall, Emma Dean, Bristi Basu, Angela George, Stan B. Kaye, Susana Banerjee, Johann S. de Bono	2017	12
13	First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·Rajiv Kumar, Joaquı́n Mateo, Alan D. Smith, Khurum Khan, Ruth Ruddle, Karen E. Swales, Shaun Decordova, Zoe Backholer, Paul S. Jones, Christine Tran, Satyanarayana Seeramreddi, Robert McLeod, Timothy A. Yap, Florence I. Raynaud, Michelle D. Garrett, Udai Banerji	2014	9
14	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes Molecular Cancer Therapeutics ·Elizabeth A. Coker, Adam Stewart, Buğra Özer, Anna Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary O’Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al‐Lazikani, Udai Banerji	2022	8
15	A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers. Journal of Clinical Oncology ·D. Papadatos-Pastos, Rajiv Kumar, Timothy A. Yap, Ruth Ruddle, Shaun Decordova, Paul S. Jones, Gavin Halbert, Michelle D. Garrett, Robert McLeod, Zoe Backholer, Karen E. Swales, Florence I. Raynaud, Johann S. de Bono, Udai Banerji	2015	8
16	Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation Metabolomics ·Ákos Pál, Yasmin J. Asad, Ruth Ruddle, Alan T. Henley, Karen E. Swales, Shaun Decordova, Suzanne A. Eccles, Ian Collins, Michelle D. Garrett, Johann S. de Bono, Udai Banerji, Florence I. Raynaud	2020	3
17	A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies British Journal of Cancer ·T. Benepal, Ann L. Jackman, L Pyle, S Bate, Anthea Hardcastle, Wynne Aherne, F. Mitchell, Laura K. Simmons, Ruth Ruddle, Florence I. Raynaud, Martin Gore	2005	3
18	TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. Journal of Clinical Oncology ·Desamparados Roda, Han Hsi Wong, Elena Geuna, Saeed Rafii, Ruth Ruddle, Angela Hayes, Karen E. Swales, Sarah Jane Stimpson, Nitharsan Sathiyayogan, Nina Tunariu, Alison Turner, Emma Hall, Timothy A. Yap, Susana Banerjee, Mary O’Brien, L. Rhoda Molife, Stan B. Kaye, Johann S. de Bono, Bristi Basu, Udai Banerji	2014	2
19	DIPG-29. PRECLINICAL EFFICACY OF COMBINED ACVR1 AND PI3K/mTOR INHIBITION IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) Neuro-Oncology ·Diana Carvalho, Nagore G. Olaciregui, Ruth Ruddle, Adam Donovan, Ákos Pál, Florence I. Raynaud, Peter J. Richardson, Ángel M. Carcaboso, Chris Jones	2018	2
20	Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors Molecular Cancer Therapeutics ·Udai Banerji, Simon Pacey, Karen Finkelstein, Simon Rodney, Ana Filipa Palma DosReis, Giovanni Codacci-Pisanelli, Mark Sloan, Florence I. Raynaud, Ruth Ruddle, Karen E. Swales, Matthew Tall, Shay Shemesh, Diane Marsolini, Megan Sardone, Justin L. Hay, Robin Bliss, Enrique Poradosu, Paul Workman	2023	1

About Ruth Ruddle

Ruth Ruddle is a scholar working on Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine, Oncology and Organic Chemistry, having authored 23 papers that have together received 652 indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Biochemical and Molecular Research (4 papers), Cancer Treatment and Pharmacology (3 papers), Lung Cancer Treatments and Mutations (3 papers), Colorectal Cancer Treatments and Studies (2 papers), Quinazolinone synthesis and applications (2 papers) and Advanced MRI Techniques and Applications (2 papers). The work is most often cited by research in Cancer Research (98 citations), Molecular Biology (409 citations), Oncology (137 citations), Cell Biology (62 citations) and Pathology and Forensic Medicine (66 citations). Ruth Ruddle has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Florence I. Raynaud, Paul Workman, Suzanne A. Eccles, Melanie Valenti, Michelle D. Garrett, Alexis de Haven Brandon, Ian Collins, John Caldwell, Wynne Aherne and Kevin Taylor. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, Cancer Research, Clinical Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Ruth Ruddle

Impact in

Papers in i

In The Last Decade

Ruth Ruddle

Peers

Countries citing papers authored by Ruth Ruddle

Fields of papers citing papers by Ruth Ruddle

All Works

About Ruth Ruddle

Explore authors with similar magnitude of impact

Papers in